Phreesia, Inc. (NYSE:PHR) Short Interest Down 30.2% in December

Phreesia, Inc. (NYSE:PHR) was the recipient of a large decrease in short interest during the month of December. As of December 15th, there was short interest totaling 2,427,866 shares, a decrease of 30.2% from the November 30th total of 3,479,944 shares. Based on an average daily volume of 2,620,410 shares, the short-interest ratio is currently 0.9 days. Currently, 4.3% of the shares of the stock are sold short. Currently, 4.3% of the shares of the stock are sold short. Based on an average daily volume of 2,620,410 shares, the short-interest ratio is currently 0.9 days.

Insider Activity at Phreesia

In other news, General Counsel Allison C. Hoffman sold 1,241 shares of Phreesia stock in a transaction that occurred on Friday, October 17th. The stock was sold at an average price of $22.36, for a total value of $27,748.76. Following the sale, the general counsel directly owned 135,737 shares of the company’s stock, valued at $3,035,079.32. The trade was a 0.91% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider David Linetsky sold 2,059 shares of the stock in a transaction dated Friday, October 17th. The shares were sold at an average price of $22.36, for a total transaction of $46,039.24. Following the completion of the sale, the insider owned 171,829 shares of the company’s stock, valued at $3,842,096.44. This trade represents a 1.18% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 7,534 shares of company stock valued at $165,514. 5.50% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Phreesia

Hedge funds have recently made changes to their positions in the company. Vanguard Group Inc. lifted its holdings in shares of Phreesia by 8.3% in the 3rd quarter. Vanguard Group Inc. now owns 5,704,786 shares of the company’s stock valued at $134,177,000 after purchasing an additional 437,462 shares during the last quarter. Greenhouse Funds LLLP increased its position in Phreesia by 16.8% during the third quarter. Greenhouse Funds LLLP now owns 3,882,527 shares of the company’s stock worth $91,317,000 after buying an additional 557,265 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in Phreesia by 108.7% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,644,988 shares of the company’s stock valued at $67,606,000 after buying an additional 1,377,904 shares during the last quarter. Franklin Resources Inc. boosted its holdings in shares of Phreesia by 1.9% in the third quarter. Franklin Resources Inc. now owns 1,553,192 shares of the company’s stock valued at $36,531,000 after acquiring an additional 28,941 shares during the period. Finally, Granahan Investment Management LLC grew its position in shares of Phreesia by 6.0% during the third quarter. Granahan Investment Management LLC now owns 1,380,626 shares of the company’s stock worth $32,472,000 after acquiring an additional 77,841 shares during the last quarter. Hedge funds and other institutional investors own 92.10% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on PHR. Canaccord Genuity Group dropped their target price on Phreesia from $38.00 to $33.00 and set a “buy” rating for the company in a report on Tuesday, December 9th. Zacks Research raised shares of Phreesia from a “hold” rating to a “strong-buy” rating in a research note on Monday, December 8th. Raymond James Financial set a $33.00 price target on shares of Phreesia and gave the company an “outperform” rating in a research note on Friday, September 5th. KeyCorp cut their price target on shares of Phreesia from $35.00 to $32.00 and set an “overweight” rating for the company in a report on Wednesday, October 8th. Finally, Robert W. Baird decreased their price objective on Phreesia from $31.00 to $25.00 and set an “outperform” rating on the stock in a report on Wednesday, December 10th. One investment analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $31.00.

Phreesia Stock Performance

NYSE:PHR traded down $0.03 on Monday, reaching $16.99. 910,901 shares of the company’s stock were exchanged, compared to its average volume of 1,866,219. The business has a fifty day moving average of $20.19 and a 200-day moving average of $24.35. The company has a quick ratio of 2.44, a current ratio of 2.44 and a debt-to-equity ratio of 0.01. Phreesia has a 52-week low of $15.41 and a 52-week high of $32.76.

Phreesia (NYSE:PHR) last issued its quarterly earnings results on Monday, December 8th. The company reported $0.10 earnings per share for the quarter, topping the consensus estimate of ($0.01) by $0.11. The company had revenue of $120.33 million for the quarter, compared to the consensus estimate of $119.98 million. Phreesia had a negative return on equity of 1.31% and a negative net margin of 1.16%.Phreesia’s revenue was up 12.7% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.25) EPS. Equities analysts predict that Phreesia will post -1.1 earnings per share for the current fiscal year.

Phreesia Company Profile

Phreesia, Inc (NYSE: PHR) is a provider of patient intake management solutions designed to streamline front-office workflows for healthcare organizations. The company’s cloud-based platform digitizes patient registration, appointment scheduling, insurance verification, consent documentation and payment collection through touchscreen kiosks, tablets and mobile devices. By replacing paper forms and manual processes, Phreesia enhances data accuracy, reduces administrative burden and improves the patient experience.

Founded in 2000 by Chaim Indig and headquartered in Burlington, Massachusetts, Phreesia offers a modular software suite that integrates with electronic medical record (EMR) and practice management systems.